Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pershing Square No Longer Holds A Position In Zoetis

ZTS

Billionaire investor Bill Ackman acquired an approximate 8.5 percent stake in Zoetis Inc (NYSE: ZTS), a producer of animal medicines and vaccinations, back in November 2014.

Ackman and his hedge fund Pershing Square Capital Management first bought 5.5 million shares of Zoetis in 2014 at $34 per share and added to his position over the years. The New York Times reported in May of this year that Ackman was looking to sell its entire 16.85 million share stake in Zoetis for a price range of $46.75 to $47 per share or a total consideration of around $800 million.

The New York times also noted that Ackman paid $1.5 billion for the entire stake of Zoetis.

Zoetis' stock was trading at $51.02 on Thursday.

Pershing Eliminates Its Stake

Pershing Square confirmed with Benzinga on Thursday that Ackman announced during the fund's quarterly investor call that it completed sold its stake in Zoetis.